Built upon decades of experience engineering cell lines, RNA synthesis, and bioinformatic design, we have created a unique portfolio of reagents and services that empower researchers to push their work forward with data generated from cell models.

Horizon is leveraging its technological expertise to provide cell engineering tools and services to its customers in three key areas of the therapeutic ecosystem: basic research, drug discovery and development and therapeutic applications. Some of our central services include:

• Screening & Cell line engineering services: tools and services that are designed to improve the outcome of drug discovery and development
• BioProduction cell lines: engineered CHO cell lines that are designed to enable efficient biologics manufacturing

Horizon’s customers include biopharmaceutical and diagnostics companies, contract research and manufacturing organizations and academic researchers across the globe. Horizon sells its tools and services to more than 2,000 unique customers in over 60 countries, including to 19 of the 20 largest biopharmaceutical companies by revenue.

On the contract research front, Horizon’s service group supports researchers with cell line engineering, functional genomic screening, high-throughput immuno-oncology assays, compound profiling, drug combination screening, using CRISPR, or siRNA for a variety of cell-based assays.

Horizon is now part of Revvity.

Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.